- Advanced search
- Immuno Portal
- Malaria Portal
|International Nonproprietary Names|
|Hu23F2G | LeukArrest|
|Rovelizumab (Hu23F2G) is a humanized IgG4 bispecific monoclonal antibody targeting integrin alpha L subunit (ITGAL, CD11A) and integrin beta 2 subunit (ITGB2, CD18) , which are components of the leukocyte adhesion integrin LFA-1. Rovelizumab was developed by Icos Corporation (later acquired by Eli Lilly) for potential use in multiple sclerosis, myocardial infarction and ischemic stroke.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|GtoPdb PubChem SID||340590228|
|Search PubMed clinical trials||rovelizumab|
|Search PubMed titles||rovelizumab|
|Search PubMed titles/abstracts||rovelizumab|